Tempest Therapeutics
TPST
30 hedge funds and large institutions have $8.5M invested in Tempest Therapeutics in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 12 closing their positions.
306% more call options, than puts
Call options by funds: $130K | Put options by funds: $32K
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
19% less funds holding
Funds holding: 37 → 30 (-7)
48% less capital invested
Capital invested by funds: $16.4M → $8.5M (-$7.94M)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.51M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.04M |
| 3 |
Renaissance Technologies
New York
|
+$762K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$395K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$297K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$1.98M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$1.98M |
| 3 |
Barclays
London,
United Kingdom
|
-$874K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$863K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$715K |
TPST Hedge Fund Activity: Q1 2021 in Review
30 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2021, worth a combined $8.5M — down 48% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TPST and 5 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Ikarian Capital, adding an estimated $2.51M. The largest seller was Commodore Capital, exiting entirely with an estimated $1.98M sold.
- 30 institutional investors held Tempest Therapeutics (TPST) as of Q1 2021, down from 37 in Q4 2020.
- Funds reported $8.5M of Tempest Therapeutics stock for Q1 2021, down 48% quarter-over-quarter.
- 5 funds opened new Tempest Therapeutics positions in Q1 2021 and 12 closed out, a net change of -7 holders.
- The largest Tempest Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $2.51M added.
- The largest Tempest Therapeutics seller in Q1 2021 was Commodore Capital, an estimated $1.98M sold.
Based on aggregated 13F filings for Q1 2021.